Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis

Nephrology Dialysis Transplantation

Volumn 23, Issue 4, 2008, Pages 1370-1377

  David, Sascha ^a   Kümpers, Philipp ^a   Seidler, Vega ^a   Biertz, Frank ^a   Haller, Hermann ^a   Fliser, Danilo ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Bioelectrical impedance analysis (BIA); Chronic kidney disease (CKD); Left ventricular dysfunction (LVD); Maintenance haemodialysis (HD); N terminal pro B type natriuretic peptide (NT proBNP)

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PROTEIN PRECURSOR;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIAGNOSTIC TEST; ELECTROCARDIOGRAM; EXTRACELLULAR FLUID; FEMALE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEMODIALYSIS; HUMAN; HYDRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; BLOOD; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DOPPLER ECHOCARDIOGRAPHY; FOLLOW UP; HEART STROKE VOLUME; HOSPITALIZATION; IMMUNOASSAY; IMPEDANCE; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; RENAL REPLACEMENT THERAPY;

AGED; BIOLOGICAL MARKERS; ECHOCARDIOGRAPHY, DOPPLER; ELECTRIC IMPEDANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOASSAY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROTEIN PRECURSORS; RENAL DIALYSIS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 42949086558     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm700     Document Type: Article

References (42)

1. Felker GM, Petersen JW, Mark DB. Natriuretic peptides in the diagnosis and management of heart failure. CMAJ 2006; 175: 611-617
2. Goetze JP, Christoffersen C, Perko M et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003; 17: 1105-1107
3. Konstam MA. Natriuretic peptides and cardiovascular events: more than a stretch. JAMA 2007; 297: 212-214
4. Sullivan DR, West M, Jeremy R. Utility of brain natriuretic peptide (BNP) measurement in cardiovascular disease. Heart Lung Circ 2005; 14: 78-84
5. Racek J, Kralova H, Trefil L et al. Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients. Nephron Clin Pract 2006; 103: c162-c172
6. Wang AY, Lam CW, Yu CM et al. N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol 2007; 18: 321-330
7. Khan IA, Fink J, Nass C et al. N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J Cardiol 2006; 97: 1530-1534
8. Vickery S, Price CP, John RI et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005; 46: 610-620
9. Fort J. Chronic renal failure: a cardiovascular risk factor. Kidney Int Suppl 2005: S25-S29
10. Das M, Aronow WS, McClung JA et al. Increased prevalence of coronary artery disease, silent myocardial ischemia, complex ventricular arrhythmias, atrial fibrillation, left ventricular hypertrophy, mitral annular calcium, and aortic valve calcium in patients with chronic renal insufficiency. Cardiol Rev 2006; 14: 14-17
11. Guerin AP, Pannier B, Marchais SJ et al. Cardiovascular disease in the dialysis population: prognostic significance of arterial disorders. Curr Opin Nephrol Hypertens 2006; 15: 105-110
12. Kielstein JT, Zoccali C. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis 2005; 46: 186-202
13. Dikow R, Zeier M, Ritz E. Pathophysiology of cardiovascular disease and renal failure. Cardiol Clin 2005; 23: 311-317
14. Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol 1998; 11: 239-245
15. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9 (Suppl): S16-S23
16. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (Suppl 3): S112-S119
17. Kuhlmann MK, Zhu F, Seibert E et al. Bioimpedance, dry weight and blood pressure control: new methods and consequences. Curr Opin Nephrol Hypertens 2005; 14: 543-549
18. Hall C. Essential biochemistry and physiology of (NT-pro) BNP. Eur J Heart Fail 2004; 6: 257-260
19. Hall C. NT-ProBNP: the mechanism behind the marker. J Card Fail 2005; 11 (Suppl): S81-S83
20. Suresh M, Farrington K. Natriuretic peptides and the dialysis patient. Semin Dial 2005; 18: 409-419
21. Madsen LH, Ladefoged S, Corell P et al. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int 2007; 71: 548-554
22. Ahmed A, Aronow WS, Fleg JL. Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. Am Heart J 2006; 151: 444-450
23. Jacobs C, Frei D, Perkins AC. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant 2005; 20 (Suppl 3): iii3-iii24
24. Lang RM, Bierig M, Devereux RB et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-1463
25. Quinones MA, Waggoner AD, Reduto LA et al. A new, simplified and accurate method for determining ejection fraction with two-dimensional echocardiography. Circulation 1981; 64: 744-753
26. Palazzuoli A, Silverberg D, Iovine F et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006; 152: 1096 e1099-e1015
27. Fagugli RM, Palumbo B, Ricciardi D et al. Association between brain natriuretic peptide and extracellular water in hemodialysis patients. Nephron Clin Pract 2003; 95: c60-c66
28. Sharma R, Gaze DC, Pellerin D et al. Raised plasma N-terminal pro-B-type natriuretic peptide concentrations predict mortality and cardiac disease in end-stage renal disease. Heart 2006; 92: 1518-1519
29. London GM, Guerin AP, Marchais SJ. Pathophysiology of left ventricular hypertrophy in dialysis patients. Blood Purif 1994; 12: 277-283
30. Tonelli M, Wiebe N, Culleton B et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17: 2034-2047
31. Sheen V, Bhalla V, Tulua-Tata A et al. The use of B-type natriuretic peptide to assess volume status in patients with end-stage renal disease. Am Heart J 2007; 153: 244 e241-e245
32. Guida B, De Nicola L, Trio R et al. Comparison of vector and conventional bioelectrical impedance analysis in the optimal dry weight prescription in hemodialysis. Am J Nephrol 2000; 20: 311-318
33. Kraemer M. A new model for the determination of fluid status and body composition from bioimpedance measurements. Physiol Meas 2006; 27: 901-919
34. Charra B. Fluid balance, dry weight, and blood pressure in dialysis. Hemodial Int 2007; 11: 21-31
35. Kayatas M, Ozdemir N, Muderrisoglu H et al. Comparison of the non-invasive methods estimating dry weight in hemodialysis patients. Ren Fail 2006; 28: 217-222
36. Yanagiba S, Ando Y, Kusano E et al. Utility of the inferior vena cava diameter as a marker of dry weight in nonoliguric hemodialyzed patients. ASAIO J 2001; 47: 528-532
37. Chang ST, Chen CL, Chen CC et al. Enhancement of quality of life with adjustment of dry weight by echocardiographic measurement of inferior vena cava diameter in patients undergoing chronic hemodialysis. Nephron Clin Pract 2004; 97: c90-c97
38. Katzarski KS, Nisell J, Randmaa I et al. A critical evaluation of ultrasound measurement of inferior vena cava diameter in assessing dry weight in normotensive and hypertensive hemodialysis patients. Am J Kidney Dis 1997; 30: 459-465
39. Kooman JP, Van Der Sande FM, Leunissen KM. Role of sodium and volume in the pathogenesis of hypertension in dialysis patients. Reflections on pathophysiological mechanisms. Blood Purif 2004; 22: 55-59
40. Joseph G, MacRae JM, Heidenheim AP et al. Extravascular lung water and peripheral volume status in hemodialysis patients with and without a history of heart failure. ASAIO J 2006; 52: 423-429
41. Lopez-Gomez JM, Verde E, Perez-Garcia R. Blood pressure, left ventricular hypertrophy and long-termprognosis in hemodialysis patients. Kidney Int Suppl 1998; 68: S92-S98
42. Zeng C, Wei T, Jin L et al. Value of B-type natriuretic peptide in diagnosing left ventricular dysfunction in dialysis-dependent patients. Intern Med J 2006; 36: 552-557